MedicalGold

Offering access to rare insights and exposure to under-the-radar opportunities.

[MedicalGold @MedicalGoldCa]

Clinical rationale and mechanism of action for @mindmedco MM-120:

🟢 Activates #serotonin 2A receptors
🟢 Powerfully alters perception, behavior, and mood
🟢 Durable neurogenesis
🟢 #Anxiety relief

#MedicalPsychedelics $MNMD

[MedicalGold @MedicalGoldCa]

Cybin to Participate at the 2024 Milken Institute Future of Health Summit https://t.co/1BI7CLeYAD

$CYBN CEO Doug Drysdale to speak on panel about novel approaches to mental health treatments on November 13, 2024. #Biotech #MentalHealth #neuropsychiatry

[MedicalGold @MedicalGoldCa]

AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders https://t.co/6nlcBZZW8U #Biotech #Neuroplastogens

[MedicalGold @MedicalGoldCa]

Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program https://t.co/VgLjqkuDJ0 $CYBN #MedicalPsychedelics #Phenethylamines

[MedicalGold @MedicalGoldCa]

#Psilocybin 🍄 is good for Brain Health 🧠

[Nicholas Fabiano, MD @NTFabiano]

Psilocybin leads to global increases in brain network integration.

🧵1/10

[MedicalGold @MedicalGoldCa]

DRUG Stock Goes Ballistic, Shares Rise 6,000%! Which Stocks Could Be Next In The Biopharma Space? https://t.co/kyiGycG4mm $CYBN $DRUG $MNMD $PSIL #Biopharma #Biotech #MedicalPsychedelics #MentalHealth

[MedicalGold @MedicalGoldCa]

Lundbeck to Acquire Longboard Pharmaceuticals in a US$2.6 Billion Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline https://t.co/jnB8vWtFji #Biopharma #Biotech #Neurosciences

[MedicalGold @MedicalGoldCa]

#Healthcare focused boutique investment bank, Leerink Partners, assumed coverage of Mind Medicine with an Outperform rating and $20 price target

Leerink likes the emerging #psychedelics space with increasing investment in clinical development across multiple psychiatric indications, clear FDA guidance, and more established commercial infrastructure following the launch of J&J’s Spravato.

The firm also believes MM120 has a good chance of working based on published data. $MNMD #anxiety #Biotech #depression #MedicalPsychedelics

[MedicalGold @MedicalGoldCa]

21 Stocks to Play a ‘Magical Moment’ in Healthcare https://t.co/P7gLxoxoQQ

The #Biotech IPO window is reopening.

[MedicalGold @MedicalGoldCa]

Novo Nordisk bets $600M biobucks on NanoVation's ability to take genetic medicines beyond the liver https://t.co/o9XSZ3Nq5D #Biotech #Nanotechnology

[MedicalGold @MedicalGoldCa]

5 important stats about psychedelics:

🟠 8,000,000 people took mushrooms in 2023 in the United States 🇺🇸
🟠 Nearly 4,000,000 people microdosed
🟠 61% of Americans support legal psychedelic therapy
🟠 Psychedelic use quadrupled from 2019-2023
🟠 Searches for microdosing grew by 1250% between 2015-2023

#MedicalPsychedelics #psilocybin $CMPS $CYBN $MNMD

[MedicalGold @MedicalGoldCa]

BIOVAXYS ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT https://t.co/3t9ECjL1bZ

@biovaxys CEO James Passin invests $300,000 in latest company financing. #Biotech #cancer #immunology #vaccines $BIOV.CA

[MedicalGold @MedicalGoldCa]

BioVaxys to Present New Data on its DPX Immune Educating Platform at Personalized Cancer Vaccine Summit https://t.co/HIqvQYfcR2 #Biotech #Cancer #Immunology #Vaccines $BIOV.CA

[MedicalGold @MedicalGoldCa]

$XBI #Biotech ETF consolidating near 52-week highs

[MedicalGold @MedicalGoldCa]

Lykos' woes mount as FDA expands probe into its MDMA-based research: WSJ https://t.co/IFSTxHntiJ #Biotech #MDMA #MedicalPsychedelics

[MedicalGold @MedicalGoldCa]

DPX™ formulations are not limited to cancer immunotherapies. With its unique “plug and play” cargo carrying capacity and non-circulating lipid delivery, there is potential with DPX™ to develop improved mRNA vaccines, multivalent viral vaccines, vaccines for desensitizing immune response for allergies, and other immune system diseases.

Prior preclinical and clinical studies have supported proof of concept and a superior immune response with DPX formulations for infectious diseases such as RSV, influenza, and anthrax. $BIOV.CA $MRNA #Biotech #Immunology #Vaccines

[MedicalGold @MedicalGoldCa]

The BioVaxys DPX™ antigen delivery platform's lipid-based formulation limits the release of active ingredients at the injection site and protects the active ingredients from degradation.

The “no release” mechanism allows for an active uptake of antigens into immune cells and lymph nodes with the potential for long duration of response. The MOA directly accesses and programs immune cells to instigate an immune response across a range of diseases/disorders. $BIOV.CA #antigens #Biotech #Immunology

[MedicalGold @MedicalGoldCa]

BioVaxys DPX-Based Vaccines Exhibit Robust Efficacy Across Multiple Infectious Diseases 👇 #Biotech #Viruses

The DPX technology platform is a potential game changer in the treatment of viruses and other pathogens. The DPX platform facilitates antigen delivery to regional lymph nodes and has been demonstrated to induce robust and durable T cell and B cell responses in pre-clinical and clinical studies for both cancer and infectious disease. $BIOV.CA

[BioVaxys Technology Corp. @biovaxys]

DPX can play a major role in developing more effective viral vaccines, such as multivalent mRNA DTP and multivalent flu, and vaccines for emerging global diseases such as Zika and MPox.
https://t.co/knQphfBLOw

[MedicalGold @MedicalGoldCa]

SPAYVAC FOR WILDLIFE, INC. ANNOUNCES COMPLETION OF SPAYVAC RESEARCH AND PRODUCTION FACILITY IN MADISON, WISCONSIN https://t.co/CuXR52ROvg #Biotech $BIOV.CA

[MedicalGold @MedicalGoldCa]

$MNMD:

~ On track to initiate Phase 3 clinical program for MM120 orally disintegrating tablet (ODT) in Generalized Anxiety Disorder (GAD) in the second half of 2024

~ Cash runway to 2027 (more than US$300 million in treasury)

~ Beats on EPS by $.07 https://t.co/2B5cn6nTgL #Biotech #MedicalPsychedelics

[MedicalGold @MedicalGoldCa]

MindMed presents as interesting setup heading into its quarterly earnings report tomorrow morning:

~ Short interest is up to a mind blowing 36.74% 🤯

~ $7.00 financing for total proceeds of $75 million closes today

~ Roth MKM recently upgraded MindMed to a BUY with a $36 price target

~ After the financing closes today, MNMD will have more than US$300 million in cash in its treasury (market cap = US$490 million at $6.80 share price)

MindMed Corporate Presentation - https://t.co/aRQ3gFjObv

Shorts typically gang up on companies that are cash strapped with limited financing prospects. $MNMD appears to be the exact opposite with a Fort Knox cash position and major catalyst in the form of the imminent initiation of its Pivotal/Phase 3 clinical trial for its MM120 drug candidate in generalized #anxiety disorder (GAD).

In Phase 2, MM120 demonstrated a 48% remission rate 12 weeks after a single dose.

There are 20 million adults in the 🇺🇸 with GAD and the current treatments (SSRIs, Benzos) have 50%+ failure rates, significant undesirable side effects, and long term dependence.

MM-120 activates the serotonin-2a receptors🧠and increases connectivity between brain regions. Thus, allowing different perceptions and enhance patient moods.

MM-120 offers the potential for meaningful benefits for a large segment of the population that suffers from GAD and are seeking a more durable, effective treatment. #Biotech #MedicalPsychedelics